Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orexigen Therapeutics Inc. OREXQ

Healthcare Drug Manufacturers - Major
"Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity."

Recent & Breaking News (OTCPK:OREXQ)

Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017

PR Newswire May 9, 2017

Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call

Accesswire May 9, 2017

Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare Conference

PR Newswire May 2, 2017

Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries

PR Newswire May 2, 2017

Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017

PR Newswire April 25, 2017

Research Reports Initiation on Drug Makers Stocks -- Depomed, Pernix Therapeutics, Orexigen Therapeutics, and United Therapeutics

PR Newswire April 25, 2017

Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada

PR Newswire April 25, 2017

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire April 5, 2017

Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

PR Newswire March 28, 2017

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy

PR Newswire March 27, 2017

How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma

PR Newswire March 20, 2017

Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017

PR Newswire March 7, 2017

Orexigen Therapeutics to Speak at Upcoming Investor Conferences

PR Newswire February 7, 2017

Drug Makers Stocks on Investors' Radar -- Depomed, United Therapeutics, DURECT, and Orexigen Therapeutics

PR Newswire January 31, 2017

18 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  January 25, 2017

Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A.

PR Newswire January 25, 2017

Watch These 8 Huge Call Purchases In Friday Trade

Benzinga.com  January 13, 2017

15 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  January 9, 2017

15 Biggest Mid-Day Losers For Friday

Benzinga.com  January 6, 2017

Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity"

PR Newswire January 6, 2017